Meeting
2011 ASCO Annual Meeting
The relationship between age and survival outcomes for eribulin in metastatic breast cancer.
Authors
C. Twelves
University of Leeds and St. James's University Hospital, Leeds, United Kingdom
C. Twelves , L. T. Vahdat , J. Cortes , J. Wanders , C. E. Dutcus , S. Seegobin , H. B. Muss
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Clinical Trial Registration Number
NCT00388726
Citation
J Clin Oncol 29: 2011 (suppl; abstr 1060)
Abstract #
1060
Poster Bd #
17A
Abstract Disclosures
Similar Posters
Poster
2015 Breast Cancer Symposium
Eribulin and carboplatin in heavily pretreated patients with metastatic breast cancer: A single institution experience.
First Author: Patricia Martin Romano
Poster
2015 ASCO Annual Meeting
Combination of eribulin (E) and capecitabine (C) in elderly metastatic breast cancer (MBC): Update of a new option suitable in older elderly.
First Author: Ignazio Ugo Carreca
Poster
2014 ASCO Annual Meeting
Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): A pooled analysis by HER2 and ER status.
First Author: Chris Twelves
Poster
2024 ASCO Genitourinary Cancers Symposium
Enfortumab vedotin treatment regimens and efficacy in urothelial carcinoma: The Mayo Clinic experience.
First Author: Tara Ballouz